Prior authorization denial rates aren't uniform. A plan that reports an 18% overall denial rate might be running 8% on outpatient office procedures and 40% on specialty pharmacy — which means the aggregate number is hiding the real problem. For MCO CFOs, medical directors, and VP of UM roles, the service category breakdown is where the actionable insight lives. This article gives you the 2026 benchmarks by category, the financial exposure each represents, and a framework for targeting reductions where the ROI is highest.
If you're evaluating where to focus denial rate improvement efforts, start here. The data by category tells a more specific story than the overall rate — and the ROI calculation changes depending on which category you're addressing.
The 2026 Denial Rate Landscape by Service Category
CMS reports, OIG audits, and state Medicaid filings show consistent variation in prior authorization denial rates across service categories. The differences are large enough that any MCO reporting only an aggregate denial rate is missing the picture.
| Service Category | Denial Rate Range | Primary Drivers | AI Automation Impact |
|---|---|---|---|
| Specialty pharmacy (Part B / SP) | 25–40% | Step therapy, formulary tiering, clinical criteria complexity | High — documentation capture + criteria matching |
| Inpatient hospital admissions | 18–22% | Length-of-stay disputes, medical necessity on non-emergent cases | Medium — auto-approval for protocol-clear, predictive flagging |
| Advanced imaging (MRI, CT, PET) | 15–25% | Protocol alignment, clinical justification gaps | High — guideline matching + documentation flags |
| Durable medical equipment (DME) | 12–20% | Coding errors, eligibility verification, medical necessity | High — code validation + eligibility check |
| Outpatient / office procedures | 8–15% | Documentation completeness, coding mismatches | High — pre-submission validation |
| Physical therapy / rehab | 10–18% | Visit limit documentation, medical necessity for continuation | Medium — criteria alignment for continuation requests |
| Skilled nursing facility (SNF) | 14–20% | Clinical criteria alignment, admission necessity review | Medium — criteria matching on admits and extensions |
Two patterns jump out immediately. First: pharmacy is the outlier — the highest-denial category in most MA and Medicaid plans, driven by step therapy requirements, formulary tiering, and the clinical documentation complexity of specialty drugs. Second: the categories with the highest denial rates are also the categories where documentation and coding — not clinical judgment — drive the majority of denials. That's the addressable portion.
Pharmacy: The Highest-Denial, Highest-ROI Category
Specialty pharmacy prior authorization deserves focused attention because it's simultaneously the highest-denial category and the one where the financial exposure is most acute.
The math: a mid-sized MA plan covering 50,000 members might see 800–1,200 specialty drug prior authorizations per month at a 30–40% initial denial rate. At $3,000–$8,000 per month of specialty drug cost per member on therapy, a denied specialty drug authorization doesn't just create administrative rework — it disrupts treatment continuity for members with complex conditions, which has downstream cost implications that compound the immediate denial cost.
The primary drivers in pharmacy are documentation-driven, not clinical:
- Step therapy overrides: Plans require step therapy on most specialty drugs, meaning the prior auth must document that the preferred drug was tried and failed. When this documentation is incomplete — the provider notes "tried and failed" without specificity — the review fails and a denial issues.
- Formulary tiering: When a drug falls at a tier requiring PA, the submission must include the clinical justification for the specific agent vs. the preferred alternative. Generic justifications don't survive review.
- Lab and diagnostic prerequisites: Many specialty drugs require specific lab values or diagnostic results as part of the PA. When those prerequisites aren't included in the submission, the review can't proceed.
All three are documentation gaps. AI documentation capture that pulls lab values, prior medication history, and clinical notes from the EMR — and assembles the submission with the required context — addresses the primary denial driver in pharmacy without changing clinical criteria.
Inpatient: Where the Dollar Exposure Is Largest
By total cost exposure, inpatient hospital admissions represent the largest denial-related financial risk for most MCOs — even at denial rates lower than pharmacy. A single denied inpatient authorization can represent $15,000–$80,000 in contested costs, depending on the admission type and length of stay.
The primary denial categories in inpatient:
- Length-of-stay disputes: Concurrent review on extended stays where the plan's clinical reviewer determines the continued inpatient level of care is no longer medically necessary. These denials trigger complex appeal processes and often involve peer-to-peer review.
- Admission medical necessity: For non-emergent admissions, the plan may determine the inpatient setting isn't medically necessary when an observation or outpatient alternative is appropriate. These cases involve genuine clinical judgment — but documentation quality still determines whether the denial survives appeal.
- Readmission denials: 30-day readmission reviews where the plan determines the readmission was preventable and therefore not separately payable. The documentation of the first admission's discharge planning factors heavily into these decisions.
The OIG finding that 18% of appealed denials are overturned applies to inpatient cases with particular force — because the overturn rate on length-of-stay and medical necessity denials is often higher than the average, and the cost per overturned case is substantially larger than for outpatient categories.
Financial Impact: The ROI of Targeting Each Category
When MCO leaders evaluate where to focus denial rate improvement, the right frame isn't just "reduce denials" — it's "where does reducing denials save the most money per dollar of investment?" Here's the financial logic:
Appeal processing cost
Every denied prior auth that proceeds to appeal carries $150–$300 in staff time processing costs. For a plan with 50,000 prior auths per month at an 18% denial rate: 9,000 denials. If 20% proceed to appeal: 1,800 appeal reviews, at $270,000–$540,000 per month in processing cost. Reducing the initial denial rate by even 20% eliminates 1,800 denials from the system — cutting appeal processing cost by $270,000–$540,000 monthly, plus the clinical reviewer time that was previously spent on denied-and-appealed cases.
Star Ratings exposure
CMS incorporates CAHPS member satisfaction scores — including appeals and grievances — into MA Star Ratings. Plans with elevated denial rates and poor appeal resolution speed score lower. For mid-sized MA plans, quality bonus payments tied to Star Rating thresholds represent $10–$40 million annually. A measurable denial rate reduction that moves the member experience needle on the appeals/grievance metric can protect or improve Star Ratings in ways that dwarf the direct appeal processing savings.
Medical cost leakage
When prior auth denials delay care — or cause providers and members to proceed without authorization — the downstream cost frequently exceeds the cost of the originally requested service. This is most acute in inpatient: a denied SNF authorization that delays post-acute care can extend an inpatient stay unnecessarily. A denied specialty drug that disrupts an oncology treatment plan allows disease progression that costs more to treat later. The avoidance value of preventing care disruption through lower denial rates is real but difficult to attribute specifically — which is why it often gets excluded from ROI calculations even though it's the largest financial category.
The Sequencing Question: Where to Start
For most MCOs, the ROI-optimal sequence for targeting denial rate improvements follows the data:
Start with pharmacy (highest denial rate, highest financial exposure per member on therapy). The documentation gaps driving specialty pharmacy denials are addressable with AI-assisted submission prep and eligibility validation. Plans implementing automated documentation capture for specialty pharmacy typically see 30–50% reduction in initial denial rate within 60–90 days — because the primary driver is incomplete documentation, not clinical disagreement.
Move to DME and imaging (high volume, high documentation-driven denial rate). These categories have consistent documentation failure rates (12–25%) driven by the same root cause: incomplete submission context. AI eligibility and code validation and pre-submission documentation flags handle these efficiently.
Address inpatient last (highest dollar exposure, most complex). Inpatient denial rate improvement requires a combination of documentation quality improvements for initial submissions, concurrent review tooling for length-of-stay decisions, and better first-review clinical alignment to reduce the 18% appeal overturn rate. The ROI is highest here, but the implementation complexity is also highest — which is why it's the right place to focus once documentation improvements in pharmacy and DME are delivering measurable results.
CMS 2026 Changes the Calculus on All of This
Before CMS 2026, denial rate management was an internal operational concern. The public reporting obligations in CMS-0057-F change that: MA plan denial rates are published. Medicaid MCO denial rates are disclosed to state regulators and increasingly visible to the provider community. Plans with elevated denial rates in pharmacy and inpatient — the two highest-exposure categories — are now managing a public accountability metric as well as an internal financial one.
The plans winning on this are treating denial rate reduction as a category-specific initiative rather than a general program improvement. They have the metrics broken down by service category, they're targeting the highest-leverage categories first, and they're using AI automation as the primary intervention because it delivers measurable reduction faster than process redesign alone.
Get a Category-Level Denial Rate Analysis for Your Plan
CareHive's prior authorization audit gives MCOs a service-category breakdown of denial patterns, financial exposure estimates by category, and an AI automation roadmap targeting the highest-ROI interventions. We work from your operational data — not industry averages.